Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Albany Medical Center’s adult Cystic Fibrosis Care Center has been treating patients aged 18 and older living with cystic fibrosis (CF).

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Notably, the company has announced a new Phase 2b study for its lead asset, bexotegrast, in progressive pulmonary fibrosis (PPF), which is set to begin in the second half of 2025. This new study ...

Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive brand refresh." The U.S.-based retailer boasted in a news release that the new look — its first change ...

Here are some before and after pictures of the company's wordmark and logo. Need a break? Play the USA TODAY Daily Crossword Puzzle. Here's a look at how the new wordmark and logo will appear on ...

Walmart is refreshing its logo for the first time in nearly two decades, highlighting its evolution while also serving as a nod to its past, the big-box retailer announced Monday. The word mark on ...

The CAA Foundation, the philanthropic arm of the powerhouse agency, has teamed with CORE and the Los Angeles Unified School District Education Foundation to launch the SoCal Fire Fund. Like other ...

Opinions and experiences shared by members of our community, including but not limited to people with CF and their families, belong solely to the blog post author and do not represent those of the ...

Walmart is giving its logo the first facelift in nearly two decades, rolling out a new identity that is a subtle nod to its past. The 61-year-old company unveiled Monday a refresh of its brand ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis ...